<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138579</url>
  </required_header>
  <id_info>
    <org_study_id>STP-LYM-01-V01</org_study_id>
    <nct_id>NCT01138579</nct_id>
  </id_info>
  <brief_title>Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>STP-LYM-01</acronym>
  <official_title>Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkin´s Lymphoma (NHL) After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an investigator driven, open-label, non-randomized, uncontrolled, dose
      escalating Phase I/II study evaluating the safety and preliminary efficacy of the
      trifunctional bispecific antibody FBTA05 in combination with donor lymphocyte infusions (DLI)
      for treatment of relapsed or refractory disease in CD20 positive either low- or high-grade
      non-Hodgkin´s lymphoma after allogeneic transplantation
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment delayed, trial medication no loner available
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determination of the maximum tolerated dose (MTD)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Evaluation of preliminary efficacy of FBTA05 in combination with DLI</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Leukemia</condition>
  <condition>Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FBTA05</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient´s written informed consent

          -  ≥ 18 years of age; male and female

          -  Confirmed CLL, low grade NHL or high grade NHL on standard histological or
             immunophenotypical criteria described in the WHO classification of lymphoid
             malignancies

          -  CD20 positivity (if not already confirmed)

          -  Adequate haematological, liver and kidney functions

          -  Platelet count ≥25,000mm³ (=25 x 10^9/l)

          -  Patients with active disease (relapsed/refractory) that survived at least 60 days
             after allogeneic transplantation

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt;=2 (Appendix IV)

          -  Negative pregnancy test (no more than 2 days before enrolment) and adequate
             contraception during the study in women of child bearing potential (pre- menopausal,
             &lt;2 years post-menopausal or not surgically sterile)

        Exclusion Criteria:

          -  Any anti-CD20 and / or any other anti-T cell directed antibody treatments &lt; 3 months
             before application of FBTA05

          -  Positivity for human anti-mouse antibodies (HAMAs)

          -  History of GvHD ° III or IV, or GvHD requiring steroid therapy with more than 10
             mg/day

          -  Known or suspected hypersensitivity to recombinant, murine or rat proteins

          -  AST/SGOT greater than 10 x ULN (grade 3, CTCAE)

          -  Bilirubin greater than 5 x ULN (grade 3, CTCAE)

          -  Creatinine greater than 3.5 mg/dl (grade 3, CTCAE)

          -  Acute or uncontrolled chronic infections, viral infections at risk of reactivation
             (e.g.HCV, HBV, HIV)

          -  Unable or unwilling to comply fully with the protocol

          -  Any condition which in the judgement of the Investigator would place the subject at
             undue risk or interfere with the results of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>3. Medizinische Klinik, Klinikum rechts der Isar der TU München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2010</study_first_submitted>
  <study_first_submitted_qc>June 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2010</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FBTA05</keyword>
  <keyword>CD20</keyword>
  <keyword>CLL</keyword>
  <keyword>NHL</keyword>
  <keyword>DLI</keyword>
  <keyword>allogeneic transplantation</keyword>
  <keyword>CD20 positive chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantation with active disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

